Antibody was affinity purified using an epitope specific to BHC110/LSD1 immobilized on solid support. The epitope recognized by A300-215A maps to a region between residues 50 and 100 of human FAD-binding protein BRAF35-HDAC complex 110 kDa (lysine-specific histone demethylase 1) using the numbering given in TrEMBL entry O60341 (GeneID 23028). Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
amine oxidase (flavin containing) domain 2, AOF2, BHC110, BRAF35-HDAC complex protein BHC110, CPRF, FAD-binding protein BRAF35-HDAC complex, 110 kDa subunit, flavin-containing amine oxidase domain-containing protein 2, KDM1, LSD1, lysine (K)-specific deme
between 50 and 100
2 - 8°C
Detection of human LSD1 by western blot and immunoprecipitation. Samples: Whole cell lysate from HeLa (15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 µg) and Jurkat (J; 50 µg) cells. Antibodies: Affinity purified rabbit anti-LSD1 antibody A300-215A (lot A300-215A-2) used for WB at 0.1 µg/ml (A) and 1 µg/ml (B) and used for IP at 3 µg/mg lysate. LSD1 was also immunoprecipitated by a previous lot (lot A300-215A-1) of this antibody. Detection: Chemiluminescence with exposure times of 30 seconds (A) and 10 seconds (B).
Detection of human BHC110/LSD1 by immunohistochemistry. Sample: FFPE section of human breast carcinoma. Antibody: Affinity purified rabbit anti-BHC110/LSD1 (Cat. No. A300-215A Lot2) used at a dilution of 1:1,000 (1µg/ml). Detection: DAB